DOCSLIB.ORG

The Effect of Miotics on the Intraocular Pressure of Conscious Owl Monkeys

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Miotics on the Intraocular Pressure of Conscious Owl Monkeys 848 Reports Investigative Ophthalmology October 1976 in our opinion, it should be used with some reser­ The effect of miotics on the intraocular vation as a prognostic test for the later appearance pressure of conscious owl monkeys. J. W. of glaucomatous visual field defects since the indi­ LAMBLE AND A. P. LAMBLE. vidual pressure vulnerability of the optical nerve head may vary—in this respect, even if more in­ The intraocular pressure of conscious, unsedated formative, it shares the fate of other tests for owl monkeys (Aotus trivirgatus) was measured aqueous humor dynamics. witli an applanation tonometer. Untreated eyes of the conscious animals were found to have higher From the Departments of Ophthalmology, Rigs- values than those reported for owl monkeys anes­ hospitalet and Gentofte Hospital, Copenhagen, thetized with pentobarbitone.* Locally applied Denmark. Supported by grants from the Commit­ tee for the Prevention of Blindness and artist Hjal- pilocarpine, carbachol, and oxotremorine gave con­ mar Westerdahl's Fund. Submitted for publication centration-related reductions in pressure, oxo­ March 22, 1976. Reprint requests: Ole I. Nissen, tremorine being the most potent and having Department of Ophthalmology, Rigshospitalet, longer duration of effect than the other com­ Blegdamsvej, DK 2100 Copenhagen 0, Denmark. pounds. Slight reductions were also observed with aceclidine and R.S. 86. These results are discussed Key words: acetazolamide test, facility of aqueous in relation to the effects of niiotics in man. outflow, glaucoma test, intraocular hypertension, pathological and apathological aqueous circula­ In studies on monkeys anesthetized with pento­ tion, weight tonography. barbitone, it was reported that locally adminis­ tered pilocarpine increased the outflow facility.1' 2 REFERENCES However, no significant reduction in intraocular pressure was induced by pilocarpine, but it is 1. Nissen, O. I., and Hoppe, R.: The facility of aqueous outflow calculated from the rate of notable that under the anesthetic, the basal pres­ fall in applanation pressure after intravenous sure was low even in untreated eyes. Possibly the acetazolamide in man, Acta Ophthalmol. 52: observation of Cevario and Macri:i that pento­ 390, 1974. barbitone apparently reduces aqueous inflow in 2. Nissen, O. I.: The immediate response in ap­ rhesus monkeys is significant, since pilocarpine planation pressure to intravenous acetazol­ might be unable to induce further reductions if amide in primary glaucomas and glaucoma the intraocular pressure is approaching that of the suspects, Acta Ophthalmol. 53: 537, 1975. recipient veins. 3. Grant, W. M.: Tonographic method for mea­ suring the facility and rate of aqueous flow in The present study reports the effects of several human eyes, Arch. Ophthalmol. 44: 204, parasympathomimetic drugs on the eyes of fully 1950. conscious owl monkeys, and it has been shown 4. Brubaker, R. F.: The effect of intraocular that consistent reductions in intraocular pressure pressure on conventional outflow resistance can be obtained under appropriate experimental in the enucleated human eye, INVEST. OPH­ conditions. THALMOL. 14: 286, 1975. Methods. Male owl monkeys (Aotus trivirgatus) 5. Moses, R. A.: Constant pressure applanation weighing 0.8 to 1.5 kilograms were used in groups tonography. III. The relationship of tono- of five to seven. During tonometry each animal metric pressure to rate of loss of ocular vol­ ume. Arch. Ophthalmol. 77: 181, 1967. was loosely restrained in a cloth bag which en­ 6. Thorburn, W.: Recordings of applanating veloped the trunk and limbs. After thorough train­ force at constant intraocular pressure. V. In­ ing, the animals accepted the experimental proce­ traocular volume changes due to changes in dures without apparent anxiety. The pneumatic the content of aqueous humour, Acta Oph­ tonometer using a Digilab, Inc. (Cambridge, thalmol. 51: 390, 1973. Mass.) floating probe was constructed in this 7. Levene, R., and Hyman, B.: The effect of in­ laboratory. Oxygen was admitted to the probe at a traocular pressure on the facility of outflow, pressure of 34.5 kPa. (5 p.s.i.) and the recordings Exp. Eye Res. 8: 116, 1969. were made using a Bell & Howell (Pasadena, 8. Ellingsen, B., and Grant, W. M.: The rela­ tionship of pressure and aqueous outflow in Calif.) transducer (4-421-001) and transducer in­ enucleated human eyes, INVEST. OPH­ dicator (1-176) and an Omniscribe pen recorder THALMOL. 10: 430, 1971. (Houston Instrument Div., Bausch & Lomb, Inc., 9. Johnstone, M. A., and Grant, W. M.: Pres­ Bellaire, Texas). Open-stopcock manometric cali­ sure-dependent changes in structures of the bration was carried out on five eyes of anes­ aqueous outflow system of human and mon­ thetized owl monkeys. key eyes, Am. J. Ophthalmol. 75: 365, 1973. The parasympathomimetic drugs were dissolved 10. Grierson, I., and Lee, W. R.: Changes in the in sterile physiological saline, and 10 or 20 /d of monkey outflow apparatus at graded levels of intraocular pressure: a qualitative analysis by a given solution was administered topically to each light microscopy and scanning electron mi­ croscopy, Exp. Eye Res. 19: 21, 1974. * Pentobarbitone = pentobarbital. Downloaded from iovs.arvojournals.org on 09/28/2021 Volume 15 Reports 849 Number 10 Z 4-0h 001 CONCENTRATION Fig. 1. The concentration-effect curves for oxotremorine (H), pilocarpine (•) and carbachol (A). Responses are expressed as the mean (- S.E.M.) of the greatest differences in intraocular pressure between the treated eyes and the untreated eyes observed after drug treatment. The number of animals receiving each treatment is shown. eye with an Eppendorf micropipette. Local anes­ prevent confusion of any physiological variation thesia for tonometry was induced by instillation in pressure with the drug effects. of 0.02 ml. of an 0.5 per cent oxybuprocaine hy­ Pilocarpine hydrochloride 0.25 to 2.0 per cent, drochloride solution prepared in sterile saline. carbachol (carbamyl choline chloride) 0.25 to Pressure values are given as the mean ± stan­ 4.0 per cent, and oxotremorine 0.005 to 0.5 per dard error. Comparisons have been made using cent all gave concentration-related decreases in two-sample or paired-difference t tests. intraocular pressure. Their effects are illustrated Results. In a preliminary experiment on owl in Fig. 1 in which the drug concentrations are monkeys treated only with local anesthetic for given in molar terms. Results are expressed as the tonometry, it was found that the mean intraocular mean of the greatest differences in tension ob­ pressure ± S.E.M. was 25.95 ± 1.09 mm. Hg served between treated and untreated eyes after at 1000 hours Greenwich Mean Time. Observed drug administration. It can be seen that oxotrem­ at hourly intervals for 6 hours, the individual orine is more potent than the other agents. With eyes showed physiological variation of up to 4.27 0.5 per cent oxotremorine, systemic parasympatho­ mm. Hg. However, the opposite eyes of the ani­ mimetic effects were apparent, i.e. salivation and mals varied similarly and at no time was a signifi­ diarrhea, in three of the seven animals tested and, cant difference detected, with the paired t test, therefore, higher concentrations were not tested. between the right eye and the left eye values of The time courses of responses to approximately the group. Therefore, in experiments to show equipotent submaximal concentrations of the three drug effects, only one eye of each monkey was drugs are illustrated in Fig. 2 and it is seen that treated, and the responses have been expressed the duration of effect varies in this order: oxo­ as the difference in pressure between the treated tremorine > carbachol > pilocarpine. eye and the control opposite eye, in order to Two other agents were also investigated: (-)- Downloaded from iovs.arvojournals.org on 09/28/2021 850 Reports Investigative Ophthalmology October 1976 oh I E E -2h b < TIME (hr) Fig. 2. The time course of responses to submaximal concentrations of • oxotremorine (0.025 per cent), • pilocarpine (0.5 per cent) and A carbachol (0.5 per cent) on groups of six or seven owl monkeys. Responses are expressed as the mean difference in intraocular pressure between the treated eyes and the untreated eyes (± S.E.M. where relevant). aceclidine hydrochloride and R.S. 86 (spiro-(N'- Discussion. The owl monkey is of the class methyl-piperidyl-4'-) -N-ethyl succinimide hydro- Simiae and has a trabecular plexus similar to that bromide, Sandoz). One hour after administration of man.4 Its eyes are large and this allows tonom­ of 0.5 per cent aceclidine a significant (p <0.02) etry to be performed easily. However, one pos­ increase of 2.29 ± 0.75 mm. Hg in the mean in­ sibly relevant structural difference compared with traocular pressure of the treated eyes over con­ man is that the vitreous is a viscous liquid. trol eyes was observed, although the values re­ The intraocular pressure of owl monkeys under turned to control levels after 2 hours. A small but pentobarbitone anesthesia has been measured by significant (p. <0.01) reduction of 2.24 ± 0.68 several workers. Mims and Holland4 obtained mm. Hg was observed 1 hour after administration values of 15.7 mm. Hg by Schi0tz tonometry, of 1.0 per cent aceclydine, but pressures were 13.2 mm. Hg by applanation tonometry, and 14.1 again at control levels after 2 hours. R.S. 86, 0.5 mm. Hg by manometry. Swietliczko and David5 per cent, gave no significant effect on intraocular obtained a mean value of 14.6 mm. Hg by manom­ pressure, although a 1.0 per cent solution caused etry, with a range of 10.2 to 18.9 mm. Hg. a reduction of 3.61 ± 1.12 mm. Hg after 1 hour Similar values have been obtained manometrically which was significant (p <0.01). There was no and tonometrically in owl monkeys anesthetized significant effect after 2 hours.
Load more

Recommended publications
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • Pilocarpine (Systemic) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Pilocarpine (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Salagen Brand Names: Canada JAMP Pilocarpine; M-Pilocarpine; Salagen What is this drug used for? It is used to treat dry mouth. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to pilocarpine or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Asthma, glaucoma, liver disease, or swelling in parts of the eye. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure Pilocarpine (Systemic) 1/6 that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Drug Class Review Ophthalmic Cholinergic Agonists
    Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods .......................................................................................................................................
    [Show full text]
  • Association Between N-Desmethylclozapine and Clozapine-Induced Sialorrhea
    JPET Fast Forward. Published on August 29, 2020 as DOI: 10.1124/jpet.120.000164 This article has not been copyedited and formatted. The final version may differ from this version. 1 Title page Association between N-desmethylclozapine and clozapine-induced sialorrhea: Involvement of increased nocturnal salivary secretion via muscarinic receptors by N- desmethylclozapine Downloaded from Authors and Affiliations: Shuhei Ishikawa, PhD1, 2, a, Masaki Kobayashi, PhD1, 3, *, Naoki Hashimoto, PhD, jpet.aspetjournals.org MD4, Hideaki Mikami, BPharm1, Akihiko Tanimura, PhD5, Katsuya Narumi, PhD1, Ayako Furugen, PhD1, Ichiro Kusumi, PhD, MD4, and Ken Iseki, PhD1 at ASPET Journals on September 23, 2021 1 Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University 2 Department of Pharmacy, Hokkaido University Hospital 3 Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University 4 Department of Psychiatry, Hokkaido University Graduate School of Medicine 5 Department of Pharmacology, School of Dentistry, Health Sciences University of Hokkaido a Present address: Department of Psychiatry, Hokkaido University Hospital JPET Fast Forward. Published on August 29, 2020 as DOI: 10.1124/jpet.120.000164 This article has not been copyedited and formatted. The final version may differ from this version. 2 Running title page Association between N-desmethylclozapine and CIS Corresponding author: Masaki Kobayashi Downloaded from Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12-jo, Nishi-6-chome, jpet.aspetjournals.org Kita-ku, Sapporo 060-0812, Japan. Phone/Fax: +81-11-706-3772/3235. E-mail: [email protected] at ASPET Journals on September 23, 2021 Number of text pages: 25 Number of tables: 1 Number of figures: 6 Number of words in the Abstract: 249 Number of words in the Introduction: 686 Number of words in the Discussion: 1492 JPET Fast Forward.
    [Show full text]
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’
    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.
    [Show full text]
  • I Extemporaneously Compounded Buccal Pilocarpine Preparations
    Extemporaneously compounded buccal pilocarpine preparations, acceptability and pilot testing for the treatment of xerostomia (dry mouth) in Australia Rose Motawade Lawendy Estafanos Bachelor of Pharmacy (Honours) Master of Pharmacy A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2019 School of Pharmacy i Abstract Xerostomia, the subjective feeling of dry mouth, is characterised by hypofunctioning salivary glands in which either the quantity or quality of saliva is reduced. It is a common symptom for a variety of diseases such as rheumatic and dysmetabolic diseases, and is the primary symptom associated with Sjögren’s syndrome. Xerostomia is also caused by treatments such as radiotherapy to the head and neck region and is a side effect of a range of medications. People with xerostomia usually experience dryness of mouth, lips and throat. They are more susceptible to dental caries, oral mucositis and enhanced tooth decay. They have problems with moistening, chewing and swallowing foods and taste alterations associated with reduction in salivary flow can affect their ability to taste food. These consequences can lead to decreased food consumption, which can cause malnutrition and further suppression of their immune defence mechanisms with increased risk of morbidity and reduced quality of life. Some approaches to managing xerostomia include sipping fluids such as water more frequently to moisten the oral mucosa, chewing sugar free gum to stimulate more saliva secretion, and using saliva replacement gels or drops. However, these strategies often do not provide sufficient relief due to the short-term effect they produce. Thus, a strong rationale exists for the development and evaluation of a medication to help treat dry mouth symptoms.
    [Show full text]
  • Adverse Effects of Medications on Oral Health
    Adverse Effects of Medications on Oral Health Dr. James Krebs, BS Pharm, MS, PharmD Director of Experiential Education College of Pharmacy, University of New England Presented by: Rachel Foster PharmD Candidate, Class of 2014 University of New England October 2013 Objectives • Describe the pathophysiology of various medication-related oral reactions • Recognize the signs and symptoms associated with medication-related oral reactions • Identify the populations associated with various offending agents • Compare the treatment options for medication-related oral reactions Medication-related Oral Reactions • Stomatitis • Oral Candidiasis • Burning mouth • Gingival hyperplasia syndrome • Alterations in • Glossitis salivation • Erythema • Alterations in taste Multiforme • Halitosis • Oral pigmentation • Angioedema • Tooth discoloration • Black hairy tongue Medication-related Stomatitis • Clinical presentation – Aphthous-like ulcers, mucositis, fixed-drug eruption, lichen planus1,2 – Open sores in the mouth • Tongue, gum line, buccal membrane – Patient complaint of soreness or burning http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/92 0 http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/920 Medication-related Stomatitis • Offending agents1,2 Medication Indication Patient Population Aspirin •Heart health • >18 years old •Pain reliever • Cardiac patients NSAIDs (i.e. Ibuprofen, •Headache General population naproxen) •Pain reliever •Fever reducer Chemotherapy (i.e. •Breast cancer •Oncology patients methotrexate, 5FU, •Colon
    [Show full text]
  • Pharmaceuticals
    Tel. +27‐51‐401‐3344 www.liquidtech.co.za FAX +27‐51‐401‐9069 Analysis: Qualitative Package: Pharmaceuticals Aceclidine Bupivacaine Dihydroergotamine Aceprometazine Bupranolol Dilazep Aciclovir Buprenorphine Diltiazem Ajmaline Buspirone Diphenhydramine Aldicarb Sulphone Butaperazine Dipyridamole Aldicarb‐sulfoxide Caffeine Disopyramide alpha‐Hydroxyalprazolam Carazolol Dixyrazine alpha‐Hydroxytriazolam Carbamazepine Doxapram Alprazolam Carbinoxamine Doxepin Alprenolol Carbuterol Ecgoninemethylester Amantadine Carteolol Embutramide Amiloride Carvedilol Enalapril Aminoclonazepam 7‐ Celiprolol Ephedrine Aminoflunitrazepam 7‐ Cetirizine Eprosartan Aminonitrazepam 7‐ Chlorcyclizine Esmolol Aminophenazone Chlordiazepoxide Estazolam Aminopromazine Chlorphenethiazine Ethenzamide Amiodarone Chlorpheniramine Felodipine Amiphenazole Chlorpromazine Fenarimol Amitriptylin Chlorprothixene Fendiline Amoxicillin Cilazapril Fenetylline Amphetamine Cinnarizine Fenfluramine Apomorphine Citalopram Fentanyl Aprinidine Clemastine Fexofenadine Atenolol Clenbuterol Flecainide Atorvastatin Clobazam Fluconazole Atropine Clobutinol Flufenoxuron Aztreonam Clomethiazole Flunitrazepam Befunolol Clomipramine Fluoxetine Bendiacarb Clonazepam Fluphenazine Benzatropine Clonidine Flurazepam Benzocaine Clozapine Fluvoxamine Benzoctamine Cocaine Gabapentin Benzoylecgonine Codeine Gallopamil Berberine Coumatetralyl Glibenclamide Betaxolol Cyclicine Glibornuride Bezafibrate Demeton‐S‐methyl Glimepiride Biperiden Desalkylflurazepam Glipizide Bisoprolol Desipramine Gliquidone
    [Show full text]